Given our earlier findings that pan-cyclophilin inhibition via CRV431 or NV556 both reduced fibrosis and HCC development, but not necessarily other characteristics of NAFLD/NASH such as steatosis or inflammation, this finding was unexpected, but likely reflects differences in the loss of function models we tested. This evidence concerns the gene PPIB and metabolic dysfunction-associated steatohepatitis.